CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials
DOI 10.1055/s-0034-1374997
Bibliografische Angaben
Nachweis in CareLit
Autor:innenG Kim, J Gerich, A Salsali, T Hach, S Hantel, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, methods: SGLT2 inhibitors increase urinary glucose excretion. It is important to identify whether this promotes UTIs and/or genital infections (GTIs). Four randomized, placebo-controlled Phase III trials investigated the effect of EMPA for 24 weeks as monotherapy, add-on to metformin, add-on to metformin + SU, or add-on to pioglitazone ± metformin in patients with T2DM. Using pooled data from these trial…
Zitieren
Zitierempfehlung
G Kim, J Gerich, A Salsali, T Hach, S Hantel, HJ Woerle, UC Broedl (2014) Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374997
Mit CareLit weiterarbeiten